Italia markets closed

Chr. Hansen Holding A/S (0MR6.IL)

IOB - IOB Prezzo differito. Valuta in DKK.
Aggiungi a watchlist
445,15+6,05 (+1,38%)
Alla chiusura: 05:33PM BST
Schermo intero
Chiusura precedente439,10
Denaro435,10 x 0
Lettera454,20 x 0
Min-Max giorno434,70 - 449,50
Intervallo di 52 settimane360,20 - 604,40
Media Volume228.937
Beta (5 anni mensile)0,27
Rapporto PE (ttm)34,37
EPS (ttm)12,95
Prossima data utiliN/D
Rendimento e dividendo (futuro)7,04 (1,60%)
Data ex dividendo24 nov 2022
Stima target 1AN/D
  • GlobeNewswire

    Update on the combination of Novozymes and Chr. Hansen: Chinese merger approval granted, supporting the path to completion

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART), IN OR INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION WHERE SUCH ACTION WOULD BE UNLAWFUL. SEPTEMBER 4, 2023 On December 12, 2022, Novozymes A/S ("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") announced that Novozymes and Chr. Hansen propose to combine and create a leading global biosolutions partner by way of a statutory merger of the two companies. Re

  • GlobeNewswire

    Chr. Hansen Holding A/S Interim Report Q3 2022/23

    July 6, 2023 – Company announcement no. 7 Strong execution by the organization drives solid Q3 results Statement by CEO Mauricio Graber: “The solid results for Q3 prove the strength of the Chr. Hansen organization which continues to deliver first-class products and innovative solutions to customers around the world, while the process with Novozymes to complete the proposed merger is progressing. Organic growth came in at 9%, driven mainly by pricing initiatives. EBIT b.s.i. increased by 9% despi

  • GlobeNewswire

    Chr. Hansen Holding A/S Interim Report Q2 2022/23

    April 13, 2023 – Company announcement no. 6 A strong first half supporting the full-year outlook Statement by CEO Mauricio Graber: “The strong results for Q2 confirm the attractiveness of the markets we serve in FC&E and H&N, and the resilience of our customer-focused business model. Organic growth came in higher than expected and reached 11%, driven by both pricing initiatives and volume growth. EBIT b.s.i. increased by 8% despite higher input costs and a less favorable product mix, leading to